Type 1 Diabetes Clinical Trial
Official title:
Carbohydrate Requirements for Prolonged, Fasted Exercise With and Without Basal Rate Reductions in Individuals With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion
The purpose of this study is to compare the time spent in glucose target range (4.0-10.0 mmol/L) during exercise and in recovery using three different management strategies for prolonged aerobic exercise: A) carbohydrate dose of 0.3g/kg/hr; B) A 50 percent basal rate reduction, performed 90-minutes in advance of exercise for the duration of the activity; and C) A 50 percent basal rate reduction, performed at exercise onset, with carbohydrate dose of 0.3g/kg/hr
This project focuses on the effectiveness of various exercise strategies on the time spent in
target range during and after aerobic exercise in adults with type 1 diabetes (T1D) on
continuous subcutaneous insulin infusion (CSII).
The primary objective of the protocol is to determine if a moderate basal insulin reduction
(-50 percent of basal), performed 90-minutes before a 120-minute aerobic exercise session
(with 5-minute breaks every 30 minutes of exercise, and a ten minute break mid-exercise),
improves the time in target range compared to either a carbohydrate consumption only strategy
or insulin reduction (-50 percent) and carbohydrate consumption strategy both performed at
the onset of exercise in patients with T1D on CSII therapy. The time in target will be
determined for both the exercise period and during a 24-hour window after the end of
exercise.
In all three sessions, aerobic exercise (brisk walking) will be performed in the fasted state
(minimum 8 hours after the last meal) in the early-morning. The exercise will consist of four
30-minute bouts of walking at 40-50 percent of the participant's pre-determined aerobic
capacity, separated by 5-10 minute breaks. The participants exercise intensity will be
monitored continuously using heart rate and activity monitors. Blood glucose and blood ketone
levels will be monitored throughout exercise.
Each participant will be assigned to a sequence of the three experimental visits through a
randomization process. Each exercise session will be separated by at least two days and
participants will be expected to complete all sessions within ~ 12 weeks from the time of the
baseline/screening visit. Participants will be instructed to apply a new continuous glucose
monitor (CGM) sensor between 1-5 days prior, not to perform moderate-to-vigorous exercise 24
hours prior and refrain from caffeine and alcohol 12 hours prior to each study visit.
Participants are also instructed not to eat after 2330h the night before arriving to the
laboratory and not to give bolus insulin or perform temporary basal rate changes after 0200h
on the morning of the exercise visit. Participants are instructed to try to arrive at the
laboratory with their blood glucose between 72-270 mg/dL, with no active bolus insulin
according to personal CSII device, in the fasted state. If a bolus of insulin was given prior
to the exercise session, the session was rescheduled. Females of reproductive capacity
performed all three visits in the early follicular phase (days 1-6 of cycle). Participants
arrived at the laboratory between 0600h and 1000h. Exercise start time was between 0700h and
1045h, based on participants' choice, and the timing of exercise was kept consistent within
participants.
Following each exercise session, the participant will rest for 20-minutes and then leave the
laboratory. The participants glucose will be monitored for 24-hours after the standardized
exercise. They will also be instructed to perform a standardized basal insulin reduction
overnight to help reduce the risk of post-exercise nocturnal hypoglycemia (-20 percent from
bedtime for 6 hours).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |